PANACISE BIO, INC.

Biotech · Public

Pro-CAR T-cell therapies with prodomain-based activation in tumor microenvironment and chemokine-integrated CAR designs

Grants
$225K
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Innovative TME-specific Pro-CAR T-cells for Immunotherapy of Solid Tumors$224,991
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1400KDT, INC——
1401HOUSTON PHARMECUTICAL INC——
1402MYOFINITY BIOSCIENCES INC——
1403PANACISE BIO, INC.——
1404On Target Therapeutics, LLC——
1405CRYOCRATE LLC——
1406DD Therapeutics, LLC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.